Thomas Trimarchi - 06 Aug 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
President and COO
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
06 Aug 2024
Transactions value $
$0
Form type
4
Filing time
08 Aug 2024, 16:39:33 UTC
Previous filing
29 Jul 2024
Next filing
20 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Award $0 +19K +4.81% $0.00 414K 06 Aug 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Award $0 +3.16K $0.00 3.16K 06 Aug 2024 Common Stock 3.16K $24.87 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units (RSUs) under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest in 16 quarterly installments beginning on August 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The stock option shall vest in 16 quarterly installments beginning on August 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.